BusinessHemispherx Updates Status of Immuno-Oncology Program in Pancreatic CancerBy Nasdaq OMXJul 10, 2017, 12:30 PM UTC
BusinessHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in EuropeBy Nasdaq OMXJan 26, 2017, 3:51 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
